Livongo touts study data indicating improved glycemic control through program use
Livongo Health today released data from 2 studies of its program, touting improved glycemic control through the use of cellular enabled blood glucose devices and personalized coaching sessions.
Data came from a study of more than 10,000 individuals between October 2014 and March 2016, the company said.
“There is a growing interest around the world from employers, hospitals and health systems, and health plans on how to effectively empower people living with diabetes. For many years, different technologies have been explored to assess how individuals can better manage their condition while combating rising healthcare costs. These studies are significant because they demonstrate the clinical improvement in a measure that is universally agreed upon as a key factor in diabetes management,” CEO Glen Tullman said in prepared remarks.
The company touted improved and sustained blood glucose control, including a 0.7% reduction in HbA1c and sustained glycemic control, as well as a 33mg/dL reduction in average blood glucose levels up to 1 year later.
The study indicated a 15% average decrease in the likelihood of a day with hypoglycemia, and reduced time frames at dangerous blood glucose levels.